Praxis Precision Medicines Inc
NASDAQ:PRAX

Watchlist Manager
Praxis Precision Medicines Inc Logo
Praxis Precision Medicines Inc
NASDAQ:PRAX
Watchlist
Price: 268.95 USD -2.11% Market Closed
Market Cap: 6.7B USD

Intrinsic Value

The intrinsic value of one PRAX stock under the Base Case scenario is 71.62 USD. Compared to the current market price of 268.95 USD, Praxis Precision Medicines Inc is Overvalued by 73%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PRAX Intrinsic Value
71.62 USD
Overvaluation 73%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Praxis Precision Medicines Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about PRAX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PRAX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Praxis Precision Medicines Inc.

Explain Valuation
Compare PRAX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about PRAX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Praxis Precision Medicines Inc

Current Assets 273.8m
Cash & Short-Term Investments 267.2m
Other Current Assets 6.7m
Non-Current Assets 122.5m
Long-Term Investments 122m
PP&E 536k
Current Liabilities 52.9m
Accounts Payable 30.8m
Accrued Liabilities 22.1m
Efficiency

Free Cash Flow Analysis
Praxis Precision Medicines Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Praxis Precision Medicines Inc

Revenue
7.5m USD
Operating Expenses
-300.6m USD
Operating Income
-293.1m USD
Other Expenses
20.1m USD
Net Income
-273m USD
Fundamental Scores

PRAX Profitability Score
Profitability Due Diligence

Praxis Precision Medicines Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Praxis Precision Medicines Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

PRAX Solvency Score
Solvency Due Diligence

Praxis Precision Medicines Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Praxis Precision Medicines Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PRAX Price Targets Summary
Praxis Precision Medicines Inc

Wall Street analysts forecast PRAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRAX is 410.52 USD with a low forecast of 80.8 USD and a high forecast of 798 USD.

Lowest
Price Target
80.8 USD
70% Downside
Average
Price Target
410.52 USD
53% Upside
Highest
Price Target
798 USD
197% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Praxis Precision Medicines Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PRAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

PRAX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PRAX stock?

The intrinsic value of one PRAX stock under the Base Case scenario is 71.62 USD.

Is PRAX stock undervalued or overvalued?

Compared to the current market price of 268.95 USD, Praxis Precision Medicines Inc is Overvalued by 73%.

Back to Top